Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660

Article  CAS  PubMed  Google Scholar 

National Cancer Institute. NCCR*Explorer: An interactive website for NCCR cancer statistic. Retrieved from https://NCCRExplorer.ccdi.cancer.gov. Accessed 15 Mar 2024

Rivera-Luna R, Shalkow-Klincovstein J, Velasco-Hidalgo L et al (2014) Descriptive Epidemiology in Mexican children with cancer under an open national public health insurance program. BMC Cancer 29(14):790. https://doi.org/10.1186/1471-2407-14-790

Article  Google Scholar 

Inaba H, Pui CH (2021) Advances in the Diagnosis and Treatment of Pediatric Acute Lymphoblastic Leukemia. J Clin Med 10(9):1926. https://doi.org/10.3390/jcm10091926

Article  CAS  PubMed  PubMed Central  Google Scholar 

Inaba H, Mullighan CG (2020) Pediatric acute lymphoblastic leukemia. Haematologica 105(11):2524–2539. https://doi.org/10.3324/haematol.2020.247031.PMID:33054110;PMCID:PMC7604619

Article  CAS  PubMed  PubMed Central  Google Scholar 

Winestone LE, Aplenc R (2019) Disparities in Survival and Health Outcomes in Childhood Leukemia. Curr Hematol Malig Rep 14(3):179–186. https://doi.org/10.1007/s11899-019-00515-x

Article  PubMed  Google Scholar 

Davitt M, Gennarini L, Loeb D, Fazzari M, Hosgood HD (2023) Impact of race/ethnicity and language preferences on pediatric ALL survival outcomes. Cancer Med 11:12827–12836. https://doi.org/10.1002/cam4.5951

Article  Google Scholar 

Gupta S, Dai Y, Chen Z et al (2023) Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia: secondary analyses of eight Children’s Oncology Group cohort trials. Lancet Haematol 10(2):e129–e141. https://doi.org/10.1016/S2352-3026(22)00371-4

Article  CAS  PubMed  PubMed Central  Google Scholar 

Janitz AE, Barber R, Campbell JE et al (2022) Measuring disparities in event-free survival among children with acute lymphoblastic leukemia in an academic institute in Oklahoma, 2005–2019. Cancer Epidemiol 81:102275. https://doi.org/10.1016/j.canep.2022.102275

Article  PubMed  PubMed Central  Google Scholar 

Eche IJ, Aronowitz T (2020) A Literature Review of Racial Disparities in Overall Survival of Black Children with Acute Lymphoblastic Leukemia Compared with White Children with Acute Lymphoblastic Leukemia. J Pediatr Oncol Nurs 37(3):180–194. https://doi.org/10.1177/1043454220907547

Article  PubMed  Google Scholar 

Jaime-Pérez JC, López-Razo ON, García-Arellano G et al (2016) Results of Treating Childhood Acute Lymphoblastic Leukemia in a Low-middle Income Country: 10 Year Experience in Northeast Mexico. Arch Med Res 47(8):668–676. https://doi.org/10.1016/j.arcmed.2017.01.004

Article  PubMed  Google Scholar 

Muñoz-Aguirre P, Zapata-Tarrés M, Espinosa-Tamez P, Sánchez-Blas H, Brochier M, Lamadrid-Figueroa H (2022) Childhood acute lymphoblastic leukemia in Mexico: mortality trend analysis, 1998–2018. Salud Publica Mex 64(1):26–34. https://doi.org/10.21149/13210

Article  PubMed  Google Scholar 

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP (2007) STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370(9596):1453–7. https://doi.org/10.1016/S0140-6736(07)61602-X

Article  Google Scholar 

Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391–2405. https://doi.org/10.1182/blood-2016-03-643544

Article  CAS  PubMed  Google Scholar 

Chadha R, Udayakumar DS, Sangwan S et al (2023) Cytogenetic Risk Stratification of B-Acute Lymphoblastic Leukemia and Its Correlation with Other Prognostic Factors. Indian J Hematol Blood Transfus 39(1):141–145. https://doi.org/10.1007/s12288-022-01541-1

Article  PubMed  Google Scholar 

Pui CH, Relling MV, Sandlund JT, Downing JR, Campana D, Evans WE (2004) Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia. Ann Hematol 83(Suppl 1):S124–S126. https://doi.org/10.1007/s00277-004-0850-2

Article  PubMed  Google Scholar 

Pui CH, Sandlund JT, Pei D et al (2004) Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children’s Research Hospital. Blood 104(9):2690–2696. https://doi.org/10.1182/blood-2004-04-1616

Article  CAS  PubMed  Google Scholar 

Koka A, Saygin C, Uzunaslan D, Ozdemir N, Apak H, Celkan T (2014) A 17-year experience with ALL-BFM protocol in acute lymphoblastic leukemia: prognostic predictors and interruptions during protocol. Leuk Res 38(6):699–705. https://doi.org/10.1016/j.leukres.2014.03.016

Article  PubMed  Google Scholar 

Buchmann S, Schrappe M, Baruchel A et al (2022) Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium. Blood 139(12):1785–1793. https://doi.org/10.1182/blood.2021012328

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pui CH, Yang JJ, Hunger SP et al (2015) Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. J Clin Oncol 33(27):2938–48. https://doi.org/10.1200/JCO.2014.59.1636

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pieters R, de Groot-Kruseman H, Van der Velden V et al (2016) Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group. J Clin Oncol 34(22):2591–2601. https://doi.org/10.1200/JCO.2015.64.6364

Article  PubMed  Google Scholar 

Vora A, Goulden N, Mitchell C et al (2014) Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. Lancet Oncol 15(8):809–818. https://doi.org/10.1016/S1470-2045(14)70243-8

Article  PubMed  Google Scholar 

Toft N, Birgens H, Abrahamsson J et al (2018) Results of NOPHO ALL2008 treatment for patients aged 1–45 years with acute lymphoblastic leukemia. Leukemia 32(3):606–615. https://doi.org/10.1038/leu.2017.265

Article  CAS  PubMed  Google Scholar 

Moreira DC, González-Ramella O, Echavarría Valenzuela M et al (2023) Evaluation of factors leading to poor outcomes for pediatric acute lymphoblastic leukemia in Mexico: a multi-institutional report of 2,116 patients. Front Oncol 18(13):1255555. https://doi.org/10.3389/fonc.2023.1255555

Article  CAS  Google Scholar 

Duffy C, Graetz DE, Lopez AMZ et al (2023) Retrospective analysis of outcomes for pediatric acute lymphoblastic leukemia in South American centers. Front Oncol 30(13):1254233. https://doi.org/10.3389/fonc.2023.1254233

Article  CAS  Google Scholar 

Abdelmabood S, Fouda AE, Boujettif F, Mansour A (2020) Treatment outcomes of children with acute lymphoblastic leukemia in a middle-income developing country: high mortalities, early relapses, and poor survival. J Pediatr (Rio J) 96(1):108–116. https://doi.org/10.1016/j.jped.2018.07.013

Article  PubMed  Google Scholar 

Ornelas-Sánchez M, Nuño-Vázquez L, Loera-Reyna A et al (2018) The “Golden Hour”: a capacity-building initiative to decrease life-threating complications related to neutropenic fever in patients with hematologic malignancies in low- and middle-income countries. Blood Adv 2(Suppl 1):63–66. https://doi.org/10.1182/bloodadvances.2018GS112240

Article  PubMed  PubMed Central  Google Scholar 

Espinoza D, Blanco Lopez JG, Vasquez R, Fu L et al (2023) How should childhood acute lymphoblastic leukemia relapses in low-income and middle-income countries be managed: The AHOPCA-ALL study group experience. Cancer 129(5):771–779. https://doi.org/10.1002/cncr.34572

Article  PubMed  Google Scholar 

Parker C, Waters R, Leighton C et al (2010) Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet 376(9757):2009–17. https://doi.org/10.1016/S0140-6736(10)62002-8

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shoag JM, Barredo JC, Lossos IS, Pinheiro PS (2020) Acute lymphoblastic leukemia mortality in Hispanic Americans. Leuk Lymphoma 61(11):2674–2681. https://doi.org/10.1080/10428194.2020.1779260

Article  PubMed  Google Scholar 

Mishra V, Jain S, Anand V, Malhotra P, Tejwani N, Kapoor G (2023) Impact of minimal residual disease on relapse in childhood acute lymphoblastic leukemia: Lessons learnt from a tertiary cancer center in India. Pediatr Hematol Oncol 40(6):517–528. https://doi.org/10.1080/08880018.2023.2186553

Article  PubMed  Google Scholar 

Pui CH (2020) Precision medicine in acute lymphoblastic leukemia. Front Med 14(6):689–700. https://doi.org/10.1007/s11684-020-0759-8

Article  PubMed  PubMed Central  Google Scholar 

Toksvang LN, Als-Nielsen B, Bacon C et al (2022) Thiopurine Enhanced ALL Maintenance (TEAM): study protocol for a randomized study to evaluate the improvement in disease-free survival by adding very low dose 6-thioguanine to 6-mercaptopurine/methotrexate-based maintenance therapy in pediatric and adult patients (0–45 years) with newly diagnosed B-cell precursor or T-cell acute lymphoblastic leukemia treated according to the intermediate risk-high group of the ALLTogether1 protocol. BMC Cancer 22(1):483. https://doi.org/10.1186/s12885-022-09522-3

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jeha S, Pei D, Choi J et al (2019) Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16. J Clin Oncol 37(35):3377–3391. https://doi.org/10.1200/JCO.19.01692

Article